Drug Index

Mechanism :

Olmesartan is an ARB that selectively inhibits the binding of angiotensin II to AT1, which is found in many tissues such as vascular smooth muscle and the adrenal glands. This effectively inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in a decrease in vascular resistance and blood pressure. Olmesartan is selective for AT1 and has a 12,500 times greater affinity for AT1 than the AT2 receptor. Also, unlike the well-known ARB losartan, olmesartan does not have an active metabolite or possess uricosuric effects.

Indication :

  • Hypertension

Contraindications :

Dehydrated patients, Liver disease, CHF, Diabetics taking medication containing aliskiren.

Dosing :

Use in children 6 to 16 years of age.
20 to <35 kg: Initial:
10 mg orally once daily; Maximum 20 mg/day.
>35 kg:
20 mg orally once daily; Maximum: 40 mg/day.

Adverse Effect :

Blood in the urine, body aches or pain, runny nose, nasal congestion, sinusitis, sore throat, chills, fever, headache, bronchitis, difficulty with breathing, cough, sneezing, dizziness, fatigue, hyperglycemia, hypertriglyceridemia.

Interaction :

Drospirenone: Increased risk of hyperkalemia.
Tobramycin: Increased risk of nephrotoxicity.
Trandolapril: The angiotensin II receptor blocker, Olmesartan, may increase the adverse effects of Trandolapril.
Treprostinil: Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function. Start with low doses
<10Dose as in normal renal function Initial dose 10 mg daily and gradually increase

Dose in Patients undergoing Renal Replacement Therapies
CAPDNot dialysed. Dose as in GFR<10 mL/min
HDNot dialysed. Dose as in GFR<10 mL/min
HDF/High fluxUnlikely to be dialysed. Dose as in GFR<10 mL/min
CAV/VVHDUnknown dialysability. Dose as in GFR=10–20 mL/min

Hepatic Dose :

based on experience in adult patients, no initial dosage adjustment may be necessary; however, in adult patients with moderate hepatic impairment, an increase in AUC of ~60% was observed; use with caution.
09/28/2020 08:10:22 Olmesartan
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0